
Moderna Rises, La-Z Boy Drops, Norfolk Southern Corp Climbs as Regulator Resumes Review of Bid From Rival
On this episode of Stock Movers:
- Moderna (MRNA) shares rise. A personalized vaccine developed by Moderna Inc. and Merck & Co. helped reduce the recurrence of melanoma in a large, late-stage trial. The trial met its main goal of showing that the vaccine, combined with Merck’s immune drug Keytruda, reduced melanoma recurrences more than the immunotherapy alone. The companies will discuss filing for approval with regulators and will present the data at an upcoming medical meeting, with Moderna Chief Executive Officer Stéphane Bancel saying the product could be approved as soon as…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.